This article first appeared on GuruFocus.
-
Cash-based Operating Expenses: $28.5 million for the quarter ended September 30, 2025, compared to $18.2 million in the same period last year.
-
Net Loss: $33.7 million for the quarter ended September 30, 2025, compared to a net loss of $41.9 million in the same period last year.
-
Cash Flows Used in Operating Activities: $34.5 million for the quarter ended September 30, 2025, compared to $19.1 million in the same period last year.
-
Operating Loss: $28.9 million for the quarter.
-
Net Loss per Share: $1.39 per basic and diluted share based on a weighted average share count of 24.2 million shares.
-
Cash, Cash Equivalents, and Investments: $83.8 million at the end of the quarter.
-
Recent Financing: Closed a $175 million financing subsequent to quarter end.
Release Date: November 13, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
-
Cybin Inc (CYBN) has successfully completed enrollment for its Phase 2 CYB004 study, which is on track for a top-line readout in the first quarter of 2026.
-
The company has strengthened its capital position with a $175 million financing, providing flexibility to execute upcoming milestones.
-
CYB003, Cybin’s proprietary deuterated psilocin analog, is progressing in Phase 3 studies and has been granted breakthrough therapy designation for major depressive disorder.
-
Cybin Inc (CYBN) has established a manufacturing partnership with Thermo Fisher, ensuring a dependable supply chain for Phase 3 and commercialization.
-
The company is actively engaging with psychiatric practices through a partnership with Osmind, facilitating the integration of its protocols into existing clinic workflows.
-
Cybin Inc (CYBN) is currently undergoing a leadership transition, with an interim CEO in place and a search for a permanent CEO ongoing.
-
The company’s cash-based operating expenses have increased significantly, totaling $28.5 million for the quarter ended September 30, 2025, compared to $18.2 million in the same period last year.
-
Net loss for the quarter was $33.7 million, indicating ongoing financial challenges.
-
There is competition for resources at clinical trial sites, which could impact the timely execution of trials.
-
The CYB004 study is not fully powered, and the company is primarily looking for directional data rather than statistically significant results.
Q: What are the expectations for the CYB004 study in terms of data readout and progression to Phase 3 trials? A: Amir Inamdar, Chief Medical Officer: The CYB004 study, which completed enrollment, is expected to provide top-line data in the first quarter of 2026. The study aims to show directional data and dose response, with statistical significance being ideal but not necessary for progression. The primary endpoint data will be shared through 12 weeks.